Latest news

• FDA knocks back DBV’s peanut allergy therapy once again

  Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... The setback means that DBV’s drug loses further ground

• Aimmune’s Palforzia is first peanut allergy drug cleared in US

  California biotech Aimmune has been in a race to market with rival companies like France’s DBV Technologies, which filed for approval of its Viaskin Peanut skin patch-based product at ... DBV’s share price in the last few weeks.

• Aimmune gets FDA panel backing for peanut allergy therapy

  of rivals including DBV Technologies which has a patch-based immunotherapy product in late-stage development. ... DBV was forced to withdraw the US marketing application for its Viaskin Peanut patch product last December after the FDA expressed concerns

• DBV refiles peanut allergy immunotherapy in the US

  Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... DBV says its new filing “incorporates additional data needs on

• Aimmune wins over ICER for peanut allergy product

  Aimmune is currently leading the race to bring a peanut allergy therapy to market, after its main rival DBV Technologies decided to withdraw the marketing application for its Viaskin Peanut patch ... DBV has said it intends to refile with the US agency